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Sex, ApoE4 and Alzheimer’s disease: 
rethinking drug discovery in the era 
of precision medicine
Alzheimer’s disease (AD) is the most common 
cause of dementia and presents with an 
insidious onset and long prodromal period. 
Despite billions spent on clinical trials and 
decades of research, there are currently no 
disease modifying therapies approved for AD.
Two of the most well-appreciated risk factors 
for AD include female sex and the presence 
of the apolipoprotein ε4 allele (APOE4; Riedel 
et al., 2016). In this Perspective, we highlight 
how greater disease subtyping through 
consideration of sex and APOE4 has the 
potential to elucidate new disease mechanisms, 
biomarkers and therapeutic strategies in AD 
(Figure 1). 
While a number of genetic variants have 
been associated with AD, APOE4 is the most 
common genetic risk factor for late onset 
AD. In the brain, apolipoprotein E (APOE) 
is produced by astrocytes and functions to 
transport cholesterol to neurons via APOE 
receptor signaling. In humans, APOE exists 
as three major isoforms, APOE2, APOE3, and 
APOE4, encoded by the ε2, ε3, and ε4 alleles, 
respectively. The ε2 allele confers protection 
against AD while the ε4 allele increases genetic 
risk for developing AD in a dose-dependent 
manner. For example, a meta-analysis among 
White cohorts demonstrated that a single 
copy of ε4 confers a 3 to 4-fold increased 
risk of developing AD (Farrer et al., 1997). 
Meanwhile, two copies of ε4 is associated with 
a 15-fold increased risk of AD. In contrast, the 
ε2 allele is associated with a 0.6-fold lower 
risk of AD. The role of APOE4 as a regulator 
of neuroinflammation is increasingly well 
appreciated and though to partly underlie 
APOE4-mediated risk in AD. For example, mice 
with an extra copy of the APOE4 allele exhibit a 
heightened immune response to liposaccharide 
compared mice with the APOE ε3 allele, 
suggesting a role of APOE4 in regulating both 
adaptive and innate immune activity (Lynch et 
al., 2003). Meanwhile young and middle aged 
APOE4 carriers have increased plasma levels of 
multiple proinflammatory cytokines, suggesting 
an elevated immune response that declines 
in later life (Ringman et al., 2012). Another 
mechanism underlying APOE4-mediated risk 
in AD might be through metal toxicity. Recent 
evidence also suggests APOE4 sequesters zinc, 
copper and iron inside neurons, leading to 
tau hyperphosphorylation and amyloid-beta 
aggregation (Xu et al., 2014).
In addition to APOE4, sex is another major risk 
factor in AD. After the age of 65, female sex is 
associated a two-fold increased lifetime risk of 
AD (Riedel et al., 2016). Interestingly, studies 
examining sex differences in cerebrospinal fluid 
(CSF) tau, CSF Aβ, brain atrophy have produced 
inconsistent results. Some have hypothesized 
that the increased lifetime risk of AD among 
females may result from an increased life 
expectancy for females (Mielke,  2018). 
Alternatively, some studies have provided 
support for the age related loss of sex steroid 
hormones including estrogen, which is known 
to protect against AD pathogenesis (Pike et 
al., 2009). Despite the therapeutic potential 
of a better understanding of these molecular 
mechanisms, sex differences in AD remain 
poorly understood.  
Recent epidemiological, imaging, and molecular 
studies have revealed that the effect of the 
APOE4 isoform on AD risk is stronger in females 
than in males. Altmann et al. (2014) applied 
Cox-proportional hazards models to examine 
the APOE4 interaction in conversion risk, from 
healthy aging to mild cognitive impairment 
(MCI) or AD and from MCI to AD in > 8000 
patients. The authors found that in both 
conversions, the hazard ratio (HR) for women 
was higher (healthy to MCI or AD HR = 2.16 
for women, 1.64 for men; MCI to AD HR = 
1.81 for women, 1.27 for men). Notably, the 
interaction term of ApoE4-sex was significant 
in the healthy aging to diseased conversion (P 
= 0.01), but not in the MCI to AD conversion. 
The interaction term was also significant in sub-
analyses restricted to ApoE3/3 and ApoE3/4 
genotypes for both conversions. Using data 
from the Alzheimer’s Disease Neuroimaging 
Initiative, Altmann et al. (2014) also identified 
a significant ApoE4-sex interaction in CSF 
(cerebrospinal fluid) biomarker levels of total 
tau (P = 0.009) and tau/amyloid beta ratio (P 
= 0.02) among MCI patients. Sampedro et al. 
(2015) assessed the presence of an APOE4-
sex interaction on core CSF biomarkers, 
brain metabolism, and structure (evaluated 
from imaging data) in healthy elderly control 
individuals for patients from the Alzheimer’s 
Disease Neuroimaging Initiative. While the 
authors found no APOE4 -sex interaction among 
CSF biomarkers, the interaction term in the 
context of brain metabolism and structure 
was significant (Sampedro et al., 2015). Both 
female and male APOE4 carriers presented 
with widespread brain hypometabolism and 
cortical thinning compared to non-carriers. 
However, female APOE4 carriers demonstrated 
a greater degree of hypometabolism and 
atrophy compared to female non-carriers, 
whereas male APOE4 carriers showed only 
small clusters of hypometabolism and regions 
of cortical thickening compared to their non-
carrier counterparts. Their findings show that 
the effect of APOE4 on brain metabolism and 
structure is modified by sex (Sampedro et al., 
2015).
While there is substantive evidence to support 
an APOE4-sex interaction from epidemiological, 
molecular, and imaging assays, the underlying 
mechanism is not well-established. However, 
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metabolomics studies may provide potential 
mechanistic explanations. For example, Zhao et 
al. (2020) generated brain transcriptomic and 
blood metabolomic data from APOE2, APOE3, 
and APOE4 targeted-replacement mice. Age, 
sex, and APOE4 status exhibited a significant 
interaction effect on genes expression within 
the unfolded protein response pathway. 
The unfolded protein response pathway is 
responsible for protecting cells from the 
harmful effects of misfolded proteins when the 
cellular environment overwhelm the ability of 
the endoplasmic reticulum to fold and assemble 
secretory proteins. Because AD is characterized 
by the accumulation of misfolded amyloid and 
tau proteins it is plausible that an increased 
vulnerability to the pathological effects of 
misfolded proteins may underlie APOE-by-sex 
interaction effects in AD. Alternately, a human 
serum metabolomics study conducted by 
Arnold et al. (2020) found that acylcarnitine 
C10 was positively correlated with CSF p-tau 
in female APOE4 carriers but not in female 
ApoE4 non-carr iers or males.  S imilar ly, 
among female APOE4 carriers specifically, 
proline levels were negatively correlated with 
reduced brain glucose uptake measured by 
[18F]-fluorodeoxyglucose-positron emission 
tomography (FDG-PET). These data suggest a 
defect in glucogenic energy metabolism and 
beta oxidation in female APOE4 carriers. While 
these are promising preliminary studies, much 
work remains to be done in order to fully 
untangle the complex molecular mechanisms 
underlying APOE and sex differences in AD.  
We envision a future in which, much like 
the precision immunotherapy revolution 
in oncology, greater disease subtyping will 
remarkably alter the AD therapeutic landscape. 
We highlight three clear actions, including 
redesigning clinical trials, integrating precise 
evaluation of neuroimaging endpoints, and 
leveraging large scale multiomics data, to foster 
APOE genotype- and sex-driven discovery of 
new AD therapeutics, biomarkers, and disease 
mechanisms.
First, a greater appreciation of the role of 
sex and APOE in AD has the capability to 
remarkably transform clinical trials in AD. The 
persistent failure of clinical trials may stem from 
underlying disease heterogeneity. Differences 
in disease etiology may render specif ic 
therapies to have varying degrees of efficacy in 
different populations. A promising step forward 
in disease subtyping in AD is the creation of the 
A/T/N (A/N/T stands for β-amyloid pathology/
tau pathology/other nonspecific biomarkers 
of neurodegeneration) disease classification 
scheme in which individuals are characterized 
by their amyloid (measured by amyloid PET 
or CSF Aβ42), tau (CSF phosphorylated tau, or 
tau PET), neurodegenerative status (FDG-PET, 
structural MRI, or CSF total tau). In the future, 
patients should be enrolled in trials based on a 
combination of cognitive assessments and their 
place on the A/T/N scheme. By gating patients 
on A/T/N cluster, pharmaceutical interventions 
may be assessed in specific disease subtypes, 
accounting for heterogenous disease etiologies 
within AD. In addition to the A/T/N framework, 
clinical trials should be performed, and results 
interpreted, within specific sex and APOE- 
subgroups. For example, in trials aimed 
cognitively normal or MCI cohorts, individuals 
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most likely to develop AD could be enriched 
for selecting high risk sex APOE groups. A 
number of emerging trials have included 
post-hoc analyses, analyzing results by APOE 
genotype (Kennedy et al., 2014). While these 
are promising steps, post hoc analysis stratified 
by sex and APOE genotype should become a 
routine analysis in AD clinical trials.  
Neuroimaging techniques, including amyloid-
PET and MRI, are increasingly used as endpoints 
and selection criteria in AD clinical trials. Our 
group has recently identified an APOE-by-sex 
interaction effect on tau deposition in the brains 
of patients with MCI (Liu et al., 2019) in which 
the APOE4 allele exerts a greater effect on 
regional tau deposition in females compared to 
males. Interestingly, females may remain at the 
same level of cognitive impairment compared 
to males, in spite of a higher tau burden, 
suggesting a greater resilience to tau-mediated 
neuropathy. In light of this and other studies 
showing APOE4-by-sex interaction effects on 
brain FDG metabolism and brain structure 
(Sampedro et al., 2015), future trials using an 
imaging based endpoint or recruitment criteria 
should redefine thresholds based on sex and 
APOE4 carrier status.  
Technological advancements and the increasing 
availability of large-scale multi-omics datasets 
present a unique opportunity to create 
subtype-specific transcriptomic, metabolomics 
and genomic profiles for biomarker discovery, 
therapeutic  discovery,  and mechanist ic 
studies in AD. While APOE genotype and 
sex have previously been shown to modify 
serum and brain transcriptomic, genomic, and 
metabolomic profiles in AD (Paranjpe et al., 
2020), their interaction in these data has not 
been studied. One can imagine a paradigm 
in which the APOE4 allele leads to radically 
different pathophysiological mechanisms in 
males and females with AD. By generating 
APOE and sex- stratified multiomics profiles 
in AD, we can begin to elucidate subtype 
specific molecular candidates for therapeutic 
intervention and biomarker development. 
Numerous  large sca le  mult iomics  data 
consortia are already freely accessible to 
researchers including the Alzheimer’s Disease 
Neuroimaging Initiative and Accelerating 
Medicines Partnership. Another powerful and 
cost-effective drug development approach 
i s  re p u r p o s i n g  ex i s t i n g  F DA- a p p rove d 
medications. Powerful new computational 
techniques including transcriptome and 
genomic-guided drug repurposing as well as 
literature-based drug repurposing have set 
the stage for researchers to identify APOE 
genotype- and sex-specific repurposed drugs in 
AD (Paranjpe et al., 2019).
In summary, the past several decades has 
seen billions of dollars in R&D spend with few 
therapeutic successes. With a growing global 
elderly population, there exists a substantial 
need to implement creative strategies to 
usher in a new generation of pharmaceutical 
approaches to AD. We are cautiously optimistic 
that a greater focus on disease subtyping 
through the inclusion of sex and the APOE 
genotype has the potential to elucidate new 
therapies and unlock the power of precision 
medicine in AD.  
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Figure 1 ｜ Greater disease subtyping through consideration of sex and APOE4 has the potential to 
remarkably transform the AD clinical trial landscape and basic science research paradigm. 
In this Perspective, we highlight implications in clinical trial design, neuroimaging evaluation protocol, and 
usage of large-scale multiomics data to improve subtype-specific biomarker and therapeutic discovery for 
AD. AD: Alzheimer’s disease; APOE4: apolipoprotein ε4 allele.
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